Mitralign, Inc. Company Profile
Mitralign is a cardiac device company founded by the Accelerated Technologies (ATI) medical device incubator. The company has developed and is currently testing an innovative, catheter-based valve repair technology for first-line percutaneous treatment of functional mitral regurgitation. The novel technology emulates surgical annuloplasty as it delivers a pair of surgical implants directly into the mitral annulus through a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and shifting the valve leaflets closer together. The location of the implants, the extent of the cinching and the number of implants can potentially be customized according to the needs of each patient. Once the procedure is completed, therapeutic options remain open, a desirable characteristic of a first-line therapy. For additional details, please refer to the website: www.mitralign.com
FARMINGTON, Conn. and TEWKSBURY, Mass., Sept. 11, 2012 (GLOBE NEWSWIRE) -- Horizon Technology Finance Corporation (Nasdaq:HRZN) ("Horizon"), a leading specialty finance company that provides secured...
A debt funding round has brought in $7 million for Mitralign. -More-
Drugs and Medications
Mitralign is a cardiac device company founded by the Accelerated Technologies (ATI) medical device incubator. The company has developed and is currently testing an innovative, cat...
More Information about "Mitralign, Inc." on BioPortfolio
We have published hundreds of Mitralign, Inc. news stories on BioPortfolio along with dozens of Mitralign, Inc. Clinical Trials and PubMed Articles about Mitralign, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mitralign, Inc. Companies in our database. You can also find out about relevant Mitralign, Inc. Drugs and Medications on this site too.